News

How is COVID-19 impacting payers and HTA decisions across the EU? What are the implications for patient access for new pharmaceutical products?

Given the unprecedented global shutdown occurring in response to COVID-19, payers and HTA bodies are struggling to adjust to the new way of working. What impact is this having on existing drugs that are currently undergoing pricing, reimbursement and health technology assessments? How has each country adapted to the challenges?

Summary of how HTA bodies decision making for new medicines are affected by COVID-19

UK: The National Institute for Health and Care Excellence (NICE)

NICE have announced they are stopping all non-critical NICE assessments. Only “therapeutically critical” assessments and COVID-19 diagnostic or therapeutic interventions will be undertaken in the short term, due to the pressures put on the NHS. In practice, this means all cancer medicines and a selected few non-cancer medicines. Technology Appraisal committee meetings are continuing to be held (except for April). However, these […]

By |2020-04-01T14:47:55+01:00March 31st, 2020|News|Comments Off on How is COVID-19 impacting payers and HTA decisions across the EU? What are the implications for patient access for new pharmaceutical products?

NICE postpones majority of technology appraisals due to Covid-19

NICE have recently confirmed that during this time they will be prioritising and only publishing work that is either therapeutically critical or relates to addressing COVID-19 diagnostic or therapeutic interventions. The reason for taking this approach is to avoid distracting the NHS at a time when it is facing unprecedented pressure and to release front line staff who might otherwise be engaged in our committees or guidance development.

Essentially all technology appraisals involving a cancer medicine are considered therapeutically critical, except for cancer drugs fund reviews. A small number of non-cancer medicines have also been designated as therapeutically critical.

NICE staff will continue to work on developing guidance that hasn’t been considered therapeutically critical or related to COVID-19 as much as they can where it does not require committee or engagement with front line health and care service staff.

The re-prioritisation of the work programme to focus on therapeutically critical topics has […]

By |2020-03-27T10:51:20+00:00March 27th, 2020|News|Comments Off on NICE postpones majority of technology appraisals due to Covid-19

What is a Payer?

In health care, the term ‘Payer’ generally refers to people or bodies other than the patient that finance or refund the cost of medicinal products and health services. Payers can be government ministers deciding the price or reimbursement of products at a national level, administrators within health technology assessment (HTA) bodies, medical insurance companies or they can be a pharmacist in a hospital who helps determine which products the hospital uses. In certain circumstances, the patient can also be thought of as a Payer, particularly if they must pay for the full cost of the treatment themselves.

The main objective of the Payer is to ensure that they deliver the best possible health outcomes from their budget. This means they are looking for products which offer “value for money”. In order to achieve these objectives, Payers fund new products that are either innovative, have a low impact on their budget or […]

By |2020-03-12T11:07:00+00:00March 19th, 2020|News|Comments Off on What is a Payer?

Access to orphan drugs in the EU5. What pricing and market access processes exist to encourage patient access?

Access to orphan drugs varies substantially across the EU5. Differences in national market access and reimbursement processes are an important factor in determining the extent of patient access to orphan drugs. This newsletter will discuss the variation in access to orphan drugs observed across the EU5 and mechanisms by which individual countries may encourage access.

Introduction

Orphan drugs are targeted toward treating rare diseases with smaller patient populations. Orphan designation is generally given to products targeting life-threatening or debilitating diseases where the prevalence falls below a fixed threshold (such as 5 in 10,000 in the EU) or where the profit generated by the medicine is unlikely to be sufficient to justify its research and development costs. As a result, incentives such as fee reductions, protocol assistance and ensured market exclusivity periods, are generally required to encourage the development and launch of orphan drugs.

Through these measures, access to medical interventions can be […]

By |2020-03-05T15:47:09+00:00March 5th, 2020|News|Comments Off on Access to orphan drugs in the EU5. What pricing and market access processes exist to encourage patient access?

World Pharma Pricing, Market Access and Evidence Congress

Remap Consulting are looking forward to the upcoming World Pharma Pricing Congress where we will be exhibiting.

Conference picture

Come and see us at stand 31-32, or contact us prior to the event so we can meet up and discuss your market access or pricing needs.

By |2020-02-28T16:16:05+00:00March 2nd, 2020|News|Comments Off on World Pharma Pricing, Market Access and Evidence Congress

Legislative updates in France and Italy: Price negotiations for early access programmes?

During a recent EUCOPE members meeting in Brussels, the following findings were reported:

French Social Security Financing Law (PLFSS) 2020

The PLFSS 2020 was promulgated in December 2019, with changes impacting Recommendations for Temporary Use (RTUs), Temporary Authorisations for Use (ATUs) and biosimilars. Conditions will be relaxed for RTUs, which can now be used even if another drug is licensed for the indication if the RTU is deemed to ‘meet the patient’s needs’. However, nominative ATUs can only be used when not prescribing the drug would have serious patient consequences, and a drug’s efficacy and safety must be strongly presumed. In addition:

  • The Government can now issue a maximum number of nominative ATUs.
  • The drug subject to the nominative ATU cannot have been granted marketing authorisation for another indication or have been granted a cohort ATU.
  • The Government will now also determine the price (compensation) for the nominative ATU. No further […]
By |2020-02-27T09:57:41+00:00February 27th, 2020|News|Comments Off on Legislative updates in France and Italy: Price negotiations for early access programmes?

World Pharma Pricing, Market Access & Evidence Congress

Remap Consulting are delighted to be exhibiting at this year’s World Pharma Pricing, Market Access & Evidence Congress at the Beurs van Berlage conference centre in Amsterdam on the 18th & 19th March.

We will be at stand 31-32 so why not contact us prior to the event to arrange an informal chat about your pricing & reimbursement or market access needs?

We look forward to seeing you there!

By |2020-02-25T13:39:27+00:00February 24th, 2020|News|Comments Off on World Pharma Pricing, Market Access & Evidence Congress

Fundraising for East Cheshire Hospice

The Remap Consulting team took efforts to raise some money yesterday at their offices at Alderley Park towards our Pedometer Challenge where we aim to walk to our HQ in Switzerland and back!

We’ve made it to our HQ – we just need to walk all the way back now!

To help push us on a little further, why not donate to our justgiving page: https://www.justgiving.com/fundraising/remap-consulting

By |2020-02-21T14:22:08+00:00February 21st, 2020|News|Comments Off on Fundraising for East Cheshire Hospice